bluebird bio (BLUE) FDA Extensions Likely Not an Issue with the BLA - Morgan Stanley
Tweet Send to a Friend
Morgan Stanley analyst Matthew Harrison reiterated an Underweight rating and $10.00 price target on bluebird bio (NASDAQ: BLUE) after the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
